# Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Sarcoma Treatment

> **NCT02812654** · PHASE2 · UNKNOWN · sponsor: **AC Camargo Cancer Center** · enrollment: 70 (estimated)

## Conditions studied

- Sarcoma, Soft Tissue

## Interventions

- **DRUG:** Doxorubicin
- **DRUG:** Ifosfamide
- **RADIATION:** radiotherapy

## Key facts

- **NCT ID:** NCT02812654
- **Lead sponsor:** AC Camargo Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-03
- **Primary completion:** 2018-12
- **Final completion:** 2019-03
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2016-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02812654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02812654, "Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Sarcoma Treatment". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02812654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*